Mobble
Health · Drug development · published 2026-08-25 · via MedPage Today

Bispecific Antibody Regimen Approved for HER2-Positive Upper GI Cancers

The FDA approved zanidatamab (Ziihera) combined with tislelizumab and chemotherapy as first-line treatment for unresectable or metastatic HER2-positive gastroesophageal adenocarcinoma. The approval is based on the phase III HERIZON-GEA-01 trial, which showed about a 7-month improvement in overall survival and over 4 months in progression-free survival versus trastuzumab plus chemo. Two companion diagnostic tests were also approved to identify eligible patients.

Read the full article at MedPage Today →
Related stories
Jazz's Ziihera cleared for first-line gastric cancer use · Cancer research
Biogen's felzartamab gains first regulatory nod in China for multiple myeloma · Drug development
Ivonescimab's long-term data shows reduced benefit in Chinese lung cancer patients · Cancer research
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer.” Browse more stories.